Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumour-directed immuno-oncology antibody drugs, announced on Friday that it has named Dr Malin Carlsson as its new chief operating officer, effective 1 January 2020.
Dr Carlsson most recently held the position of vice president, head of Translational Medicine at Ferring Pharmaceuticals in Copenhagen. She is a medical doctor with specialist qualifications and a PhD in clinical immunology. She also has many years of industrial experience from various senior roles in major international pharmaceutical companies such as AstraZeneca, Nycomed, Takeda and Ferring.
Per Norlén, Alligator Bioscience CEO, said, 'I am very pleased with the successful recruitment of Malin Carlsson to Alligator. Her international experience in leading clinical development and in building development organisations will significantly strengthen our clinical capacity. This is crucial in the phase we are in now, with two products on the way to phase II and another product in clinical phase I. We look forward to welcoming Malin to Lund and to our management team.'
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients